Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Annals of Surgery

Volumn 240, Issue 6, 2004, Pages 1027-1036

  Selzner, Markus ^a   Hany, Thomas F ^b   Wildbrett, Peer ^a   McCormack, Lucas ^a   Kadry, Zakiyah ^b,c   Clavien, Pierre Alain ^a,b   Jaeck, ^a   Senninger, ^a   Neuhaus, ^a   Lerut, ^a  

^a Dept of Visc and Transplant Surg ^*

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; CANCER RECURRENCE; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MEDICINE; PHYSICIAN; PRIORITY JOURNAL; RECTUM RESECTION; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; CONTRAST MEDIA; DATABASES, FACTUAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TRIIODOBENZOIC ACIDS;

EID: 10044237741     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000146145.69835.c5     Document Type: Conference Paper

References (32)

1. Parker S, Tong T, Bolden S, et al. Cancer statistics. Cancer J Clin. 1997;47:5-27.
2. Selzner M, Clavien PA. Resection of liver tumors: Special emphasis on neoadjuvant and adjuvant therapy. In: Clavien PA, editor. Malignant Liver Tumors: Current and Emerging Therapies. Malden: Blackwell Science; 1999:137-149.
3. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
4. Clavien PA, Selzner M, Rüdiger H, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with vs. without ischemic preconditioning. Ann Surg. 2003;238:843-852.
5. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480-486.
6. Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and metastasis from colorectal cancer by selective intra arterial chemotherapy. Surgery. 2002;131:433-442.
7. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-522.
8. Figueras J, Farran L, Benasco C, et al. Vascular occlusion in hepatic resections in cirrhotic rat livers: an experimental study in rats. Liver Transplant Surg. 1997;3:617-623.
9. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-321.
10. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am. 1997;77:27-48.
11. Scheele J, Stangl R, Altendorf-Hoffmann A. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13-15.
12. Warburg O, Wind F, Neglers E. On the Metabolism of Tumors in the Body. London: Constable; 1930.
13. Som P, Atkins H, Bandopadhyay D, et al. A fluorinated glucose analoge, 2-fluoro-2-deoxy-D-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-675.
14. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344:1265-1266.
15. Lowe V. Positron emission tomography scanning in lung cancer. Resp Care Clin North Am. 2003;9:119-136.
16. Lardinois D, Weder W, Hany T, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
17. Prichard R, Hill A, Skehan S, O'Higgins N. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89:389-396.
18. Lai D, Fulham M, Stephen M, et al. The role of whole-body positron emission tomography with [18]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703-707.
19. Desai C, Zervos E, Arnold M, et al. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol. 2003;10:59-64.
20. Topal B, Flamen P, Aert R, et al. Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases. EJSO. 2001;27:175-179.
21. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose. Ann Surg. 2004;240:438-447.
22. Hany T, Steinert H, Goerres G, et al. PET diagnostic accuracy: improvement with in-line PET-CT system: Initial results. Radiology. 2002;225: 575-581.
23. Kamel E, Hany TF, Burger C, et al. CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging. 2002;29:346-350.
24. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708.
25. Ruers T, Neeleman N, Jager G, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388-395.
26. Schiepers C, Penninckx F, Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517-522.
27. Vitola J, Delbeke D, Sandler M, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21-26.
28. Johnson K, Bakhsh A, Young D, et al. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. Dis Colon Rectum. 2001;44:354-357.
29. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-1670.
30. Fong Y, Saldinger P, Akhurst T, et al. Utility of [18]F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178:282-287.
31. Cohade C, Osman M, Leal J, et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797-1803.
32. Jaeck D, Nakano H, Bachellier P, et al. Significance of hepatic lymphe node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol. 2002;9:430-438.